Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-23-014774
Filing Date
2023-04-26
Accepted
2023-04-26 16:01:31
Documents
7
Period of Report
2023-06-08

Document Format Files

Seq Description Document Type Size
1 DEF 14A finch_2023_annual_proxy_.htm DEF 14A 824140
2 GRAPHIC img2943424_0.jpg GRAPHIC 2861
3 GRAPHIC img2943424_1.jpg GRAPHIC 5361
4 GRAPHIC img2943424_2.jpg GRAPHIC 2861
5 GRAPHIC img2943424_3.jpg GRAPHIC 5361
6 GRAPHIC img2943424_4.jpg GRAPHIC 303726
7 GRAPHIC img2943424_5.jpg GRAPHIC 191144
  Complete submission text file 0000950170-23-014774.txt   1529907
Mailing Address 200 INNER BELT ROAD SOMERVILLE MA 02143
Business Address 200 INNER BELT ROAD SOMERVILLE MA 02143 617-229-6499
Finch Therapeutics Group, Inc. (Filer) CIK: 0001733257 (see all company filings)

EIN.: 823433558 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40227 | Film No.: 23849616
SIC: 2836 Biological Products, (No Diagnostic Substances)